USSTOCK.TODAY
Regular Market
Log in Sign up

Nurix Therapeutics Inc. Shares Plunge on Sanofi Program Discontinuation

Investing.com +2 · ·by G4L

SNY Sanofi ADR
$48.12 +2.30%
View chart & analysis →
NRIX NRIX +5.49%
  1. 1Sanofi announced the discontinuation of the development of SAR448272 and the termination of Phase 1 clinical trials.
  2. 2Nurix Therapeutics Inc. shares fell 34% in Tuesday after-hours trading.
  3. 3Nurix's cash, cash equivalents, and marketable securities of $1.1 billion as of August 31, 2026, do not affect operating cash guidelines.

So what's the key point?

Sanofi announced that it is stopping the development of a drug and ending its clinical trials. Following this news, the stock price of Nurix Therapeutics Inc. fell by 34%.

Source Investing.com +2 · View original ↗

Related 3-line summaries

Sanofi raises 2026 guidance as Q3 sales reach 14.4 billion euros The Motley Fool +1 · Nov 3Regeneron Beats Q3 Revenue and Profit Estimates, Shares Rise 4% Investing.com +1 · Oct 30Sanofi and ScionX Bio enter strategic collaboration to develop mRNA therapeutics Pharmaceutical Technology +1 · Oct 21
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news